The Trump administration has opened a Section 232 national security investigation into imported medical products. It is being sold as a supply-chain resilience effort. But it is a tax on Americans that raises healthcare costs for patients.
The Commerce Department’s probe covers medical equipment, personal protective equipment, and a wide range of health technologies used every day in hospitals and clinics. The scope is so sweeping that it now threatens robotics and medical devices—the tools modern medicine depends on.
Supply-chain vulnerabilities are real. COVID exposed weaknesses, especially for critical supplies. But tariffs are the wrong tool. They do not build domestic capacity on a meaningful timeline and impose immediate costs on families.
Tariffs are taxes. They are not paid by foreign governments. They are paid by American importers and passed through to hospitals, providers, insurers, employers, and families. That is why tariffs are a particularly bad way to raise tax revenue: they hide the tax, distort decisions, and raise costs across the economy.
President Trump has highlighted the revenue appeal of tariffs in his State of the Union remarks, even suggesting tariffs could replace other taxes. But “revenue” from tariffs is money taken from Americans through higher prices at home. There is nothing conservative about a hidden tax that hits working families hardest.
Healthcare is the worst place to run this experiment. Medical supply chains are global because they rely on specialization, scale, quality controls, and reliable access to components. Even when a device is assembled in America, key parts are often sourced internationally. A tariff hits finished devices and the inputs that make them. When you tax the supply chain, you tax the care.
Hospitals cannot simply stop buying essential supplies and equipment. Providers cannot delay purchases of critical tools without affecting patient care. Higher costs do not disappear. They get passed through as higher charges, higher negotiated rates, higher premiums, and higher out-of-pocket bills.
The supply-chain mechanicsbehind this pass-through are complex. When procurement costs rise or supplies tighten, healthcare systems absorb strain, and patients feel it downstream. Tariffs are not an abstract policy lever. They land in exam rooms and operating rooms.
A large hospital system that spends hundreds of millions of dollars each year on devices and supplies can face millions—or tens of millions—more in additional costs under broad tariffs. Rural and safety-net hospitals operating on thin margins get squeezed first. The people harmed first are the people with the least ability to pay more: seniors on fixed incomes, families with high deductibles, and patients who cannot absorb another surprise bill.
Tariffs also weaken domestic competitiveness in the name of strengthening it. Medical devices operate in a globally integrated market with complex sourcing and distribution. Taxing key inputs does not make American manufacturers stronger. It raises their costs, reduces investment flexibility, and makes the sector less nimble.
If policymakers want stronger supply chains and more domestic production, they should start with the barriers at home that actually deter investment: regulatory delays, compliance burdens, and uncertainty that slow expansion. They should diversify sourcing through trusted allies and redundancy rather than pretending the U.S. can reshore everything overnight without major cost increases.
Resilience comes from competition and flexibility, not from a blunt tax that hits every hospital purchase order immediately. Free trade remains the path to prosperity because it lowers costs, expands choice, and strengthens the economy's productive capacity, including in healthcare. The same principle applies to medical tools.
If this Section 232 investigation results in more tariffs, Washington will be taxing pacemakers, insulin pumps, imaging machines, and the supplies that keep hospitals running. That does not make America healthier or safer. It makes healthcare more expensive—right when families can least afford it.
